A2A Pharmaceuticals

A2A Pharmaceuticals is dedicated to designing computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic-resistant bacterial infections. A2A Pharmaceuticals' oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and diverse solid tumors. These interactions are critical for cancer progression but non-essential in normal cells.

The antibiotic programs at A2A Pharmaceuticals target biosynthetic enzymes in gram-negative bacteria in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance, unlike the numerous follow-on antibiotics currently in development. A2A Pharmaceuticals integrates interdisciplinary ingenuity with computational tools to design new drug candidates using its proprietary SCULPT platform.

Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. A2A Pharmaceuticals is building a strong foundation for future growth and innovation in the pharmaceutical industry. We invite the manager of A2A Pharmaceuticals to create a customized and exclusive company showcase and product listing on our platform to further highlight their work.